RedChip Visibility recently issued a fourth quarter 2007 research update on Pressure BioSciences, Inc. (NASDAQ: PBIO), a life sciences company focusing exclusively on the development and commercialization of pressure cycling technology, reinstating their “Speculative Buy” rating and 12-month target price of $10.00 per share.

The report also stated that PBIO reported more than a threefold year-over-year increase in revenues in the fourth quarter of 2007 as a result of the company’s strong commercialization strategy with an expanded sales force and efficient research and development staff. Pressure BioSciences’s pressure cycling technology (PCT) has multiple applications, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, protein purification, and food safety.

The recent introductions of two new products, Proteosolve-LRS and ProteoSolve-SB kits, highlight the growing demand and number of demonstrated applications for the PCT technology in specific disease diagnosis and analysis. The report went on to state that the company’s superior technology coupled with the introduction of consumables kits will, in their opinion, accelerate sales in 2008.

Let us hear your thoughts below: